Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow. Fair value range: low $109, high $170, with mid-point at $140.
Based on our latest analysis, ZTS looks meaningfully undervalued. The current price is $76.9 versus a composite fair-value midpoint of $140 (range $109–$170), which implies roughly 81.7% upside to the midpoint.
Our composite fair-value range for ZTS is $109–$170, with a midpoint of $140. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for ZTS's archetype.
Our current rating for ZTS is Strong Buy with a confidence score of 88/100. Strong Buy. Zoetis represents an extreme value dislocation for a premier mature compounder. The $139.77 composite fair value provides massive upside against irrational market pessimism. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for ZTS are: Margin Contraction; Livestock Headwinds; Macro Demand Shock. The single biggest risk is Margin Contraction: Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.
Our current rating for ZTS is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($109–$170) versus the current price of $76.9.
ZTS is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for ZTS.